Baudax Bio (Baudax Bio) EBIT per Share : $-16.32 (TTM As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio EBIT per Share?

Baudax Bio's EBIT per Share for the three months ended in Sep. 2023 was $-0.69. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-16.32.

During the past 3 years, the average EBIT per Share Growth Rate was 74.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 56.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Baudax Bio's EBIT per Share or its related term are showing as below:

BXRXQ' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 18.9 Med: 55.5 Max: 74.8
Current: 74.8

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Baudax Bio was 74.80% per year. The lowest was 18.90% per year. And the median was 55.50% per year.

BXRXQ's 3-Year EBIT Growth Rate is ranked better than
97.78% of 1306 companies
in the Biotechnology industry
Industry Median: 3.5 vs BXRXQ: 74.80

Baudax Bio's EBIT for the three months ended in Sep. 2023 was $-5.54 Mil.

Baudax Bio EBIT per Share Historical Data

The historical data trend for Baudax Bio's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baudax Bio EBIT per Share Chart

Baudax Bio Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-10,839.33

-4,651.00

-5,749.31

-952.29

-107.66

Baudax Bio Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT per Share	Get a 7-Day Free Trial															-12.08	-12.78	-2.02	-0.83	-0.69

Baudax Bio EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Baudax Bio's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-35.743	/	0.332
=	-107.66

Baudax Bio's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-5.54	/	7.994
=	-0.69

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.32

Baudax Bio (OTCPK:BXRXQ) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Baudax Bio EBIT per Share Related Terms

Thank you for viewing the detailed overview of Baudax Bio's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Baudax Bio (Baudax Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Lapp Road, Malvern, PA, USA, 19355

Website

https://www.baudaxbio.com

Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.

Executives

Natalie Mcandrew	officer: Interim CFO	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim	director	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill	director	C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies	director	1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman	director	490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore	officer: Corporate Controller/Secretary, other: PFO and PAO	C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood	director, officer: President and CEO	88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten	officer: Chief Financial Officer	490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake	director, officer: Chief Financial Officer	KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc.	10 percent owner	1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341